EQL PHARMA AB (7JK) — Defensive Interval Ratio
EQL PHARMA AB (7JK) has a Defensive Interval Ratio of 170 days as of December 2025. Defensive assets of €81.37 Million (cash €-, short-term investments €-, receivables €81.37 Million) cover 170 days of daily cash needs of €477.72K/day. Check 7JK goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
EQL PHARMA AB Defensive Interval Ratio (2022–2025)
This chart shows how EQL PHARMA AB's Defensive Interval Ratio has evolved across 4 annual periods from 2022 to 2025. As of December 2025, the ratio stands at 170 days, meaning defensive assets of €81.37 Million can fund 170 days of operations without new revenue. Also explore EQL PHARMA AB (7JK) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Defensive Interval Ratio for EQL PHARMA AB (2022–2025)
The table below presents the year-by-year Defensive Interval Ratio for EQL PHARMA AB from 2022 to 2025, covering 4 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see 7JK market cap overview.
| Year | DIR (days) | Defensive Assets (EUR) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2025 | 208 days | €125.68 Million | €605.53K/day | €- | €- | ▲ +76 days |
| 2024 | 131 days | €58.34 Million | €443.97K/day | €- | €- | ▼ -30 days |
| 2023 | 161 days | €51.70 Million | €321.05K/day | €- | €- | ▲ +35 days |
| 2022 | 126 days | €34.10 Million | €270.57K/day | €- | €- | — |